[HTML][HTML] Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
EG Gudlaugsson, EAM Janssen - Annals of oncology, 2021 - Elsevier
Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
HP Eikesdal, S Yndestad, A Elzawahry… - 2020 - ntnuopen.ntnu.no
Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
[PDF][PDF] Olaparib monotherapy as primary treatment in unselected triple negative breast cancer 5
HP Eikesdal, S Yndestad, A Elzawahry… - academia.edu
Background: The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
HP Eikesdal, S Yndestad, A Elzawahry… - Annals of Oncology …, 2020 - europepmc.org
Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
HP Eikesdal, S Yndestad, A Elzawahry… - 2020 - bora.uib.no
Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer☆
HP Eikesdal, S Yndestad, A Elzawahry… - Annals of …, 2021 - annalsofoncology.org
Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
HP Eikesdal, S Yndestad… - Annals of oncology …, 2021 - pubmed.ncbi.nlm.nih.gov
Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
HP Eikesdal, S Yndestad, A Elzawahry… - 2020 - munin.uit.no
Background-The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
HP Eikesdal, S Yndestad, A Elzawahry… - Annals of …, 2020 - duo.uio.no
Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
[PDF][PDF] Olaparib monotherapy as primary treatment in unselected triple negative breast cancer 5
HP Eikesdal, S Yndestad, A Elzawahry… - academia.edu
Background: The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …
harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi …